Dr Anand JEYASEKHARAN
MBBS (CMC Vellore, India), MRCP (UK), PhD (Cantab), FAMS (Medical Oncology)
Singapore Translational Cancer Consortium
Principal Investigator and Facility Head (Microscopy)
Cancer Science Institute of Singapore
National University of Singapore
Assistant Director of Research (Medical Oncology)
Department of Haematology-Oncology
National University Hospital Singapore
Department of Haematology-Oncology
National University Cancer Institute, Singapore
Department of Medicine
Yong Loo Lin School of Medicine, National University of Singapore
Dr Jeyasekharan obtained his undergraduate medical degree from Christian Medical College Vellore, India in 2003. He then completed a PhD in Oncology (2008) under the mentorship of Professor Ashok Venkitaraman at the University of Cambridge UK, on a Gates Cambridge Scholarship. Following a post-doctoral fellowship in Cambridge as a Junior Research Fellow (Wolfson), he joined the National University Hospital Singapore in 2010 to complete his training in Internal Medicine, and Medical Oncology (2016). He has been active in medical research at the National University Health System, and holds a joint appointment at the Cancer Science Institute, where he has run a basic science laboratory since 2013.
Dr Jeyasekharan's clinical interest is in aggressive B-cell neoplasms, and he is currently a consultant medical oncologist on the National University Hospital lymphoma team. He also serves as the assistant director of research for the division of medical oncology at National University Hospital, and is an active member of the NUHS clinician-scientist unit, where he administers the National University Hospital Clinician-Scientist Program for Residents (NCSP-R).
National University Cancer Institute, Singapore (NCIS); Ngoi N, Lim J, Ow S, Jen WY, Lee M, Teo W, Ho J, Sundar R, Tung ML, Lee YM, Ngo E, Lim SW, Ong J, Lim F, Bonney G, Vellayappan B, Ho F, Tey J, Chan N, de Mel S, Poon M, Lee SY, Koh LP, Liu TC, Tan LK, Wong A, Wong A, Lim SE, Yeoh A, Wong JE, Tan D, Goh BC, Chng WJ, Soo R, Chee CE, Chee YL, Lee SC, Jeyasekharan AD. A Segregated-Team Model to Maintain Cancer Care During the COVID-19 Outbreak at an Academic Center in Singapore. Ann Oncol. 2020 Mar 31: S0923-7534(20)36410-3. doi: 10.1016/j.annonc.2020.03.306. PMID: 32243893
De Mel S, Rashid MBM, Zhang XY, Goh J, Lee CT, Poon LM, Chan EHL, Liu X, Chng WJ, Chee YL, Lee J, Yuen YC, Lim JQ, Chia BKH, Laurensia Y, Huang D, Pang WL, Cheah DMZ, Wong EKY, Ong CK, Tang T, Lim ST, Ng SB, Tan SY, Loi HY, Tan LK, Chow EK, Jeyasekharan AD. Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma. Blood Cancer J. 2020 Jan 27;10(1):9. doi: 10.1038/s41408-020-0276-7. PMID: 31988286
Oon ML, Hoppe MM, Fan S, Phyu T, Phuong HM, Tan SY, Hue SS, Wang S, Poon LM, Chan HLE, Lee J, Chee YL, Chng WJ, de Mel S, Liu X, Jeyasekharan AD*, Ng SB*. The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma. Leuk Lymphoma. 2019 Jul 1:1-11. doi: 10.1080/10428194.2019.1633629. PMID: 31259656
Hong G, Fan S, Phyu T, Maheshwari P, Hoppe MM, Phuong HM, de Mel S, Poon M, Ng SB, Jeyasekharan AD. Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma. J Vis Exp. 2019 Jan 9;(143). doi: 10.3791/58711. PMID: 30688307
Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2018 Dec 21:101084. doi: 10.1016/j.redox.2018. 101084. PMID: 30612957
Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for Homologous Recombination Deficiency in Cancer. J Natl Cancer Inst. 2018 July, 110(7):704-713; PMID:29788099.
Tay SH, Wong AS, Jeyasekharan AD. A patient with pembrolizumab-induced fatal polymyositis. Eur J Cancer. 2018 Jan, 91:180-182; PMID:29329695.
Ng SB, Fan S, Hoppe M, De Mel S, Jeyasekharan AD. Quantitative Analysis of a Multiplexed Immunofluorescence Panel in T-Cell Lymphoma. SLAS Technol 2017 Dec, PMID:29241019.
Jeyasekharan AD, Liu Y, Hattori H, Pisupati VN, Jonsdottir, Eeson Rajendra et al, and Venkitaraman AR. A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat Struct Mol Biol. 2013 Oct;20(10):1191-8, PMID: 24013206.
Jeyasekharan AD, Ayoub N, Ries J, Mahen R, Rajendra E, Kulkarni R, Venkitaraman AR. Regulation of Brca2 intranuclear mobility promotes its assembly on damaged DNA. Proc Natl Acad Sci USA. 2010 Dec 14;107(50):21937-42, PMID: 21098284.